Login to Your Account



Other News To Note


Tuesday, July 24, 2012
• Oxford BioMedica plc, of London, said the U.S.-based Foundation Fighting Blindness granted it a $125,000 award to support the opening of a second trial site in Paris for the UshStat Phase I/IIa study. A gene-based treatment for Usher syndrome Type 1B, UshStat is the third ocular product to enter clinical development under Oxford's collaboration with Sanofi SA, of Paris. The open-label, dose-escalation trial was initiated in February in the U.S., where it will enroll up to 18 patients. The Paris site is expected to open early next year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription